Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphoma × SNX-5422 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 7 Hematologic Neoplasms 2 Neuroendocrine Tumors 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Adenocarcinoma of Lung 1

Interventions

Rituximab 53 Cyclophosphamide 53 fludarabine 35 fludarabine phosphate 29 Filgrastim 25 Etoposide 20 Melphalan 19 Gemcitabine 17 Bendamustine Hydrochloride 17 Vincristine 15 Cytarabine 15 Peripheral Blood Stem Cell Transplantation 14 Bortezomib 14 pembrolizumab 13 aldesleukin 13 Prednisone 13 Doxorubicin 12 Sirolimus 11 Busulfan 11 obinutuzumab 10 Whole-Body Irradiation 10 Vorinostat 10 Lenalidomide 10 Dexamethasone 10 Tacrolimus 9 sargramostim 8 romidepsin 8 Radiotherapy 8 Paclitaxel 8 Nivolumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00644072 2017-07-02

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡